India’s Second Stab At Whistle Blower Policy To Curb Spurious Drug Trade
This article was originally published in PharmAsia News
Executive Summary
India is making renewed efforts to encourage whistle blowers to share leads and help weed out spurious drugs from the Indian market while blocking exports of such consignments.
You may also be interested in...
Spurious Drugs Issue: Indian Government Proposes Cash Rewards For Informers; Industry Supportive
NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.